Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

75

Participants

Timeline

Start Date

August 14, 2020

Primary Completion Date

August 16, 2021

Study Completion Date

January 31, 2022

Conditions
Alzheimer DiseaseParkinson Disease
Interventions
DRUG

Posiphen

Solid oral dosage form, capsule

DRUG

Placebo

Solid oral dosage form, capsule

Trial Locations (13)

11776

North Suffolk Neurology, PC, Port Jefferson Station

19107

Penn Medicine, Department of Neurology, U of PA, Philadelphia

30030

iResearch Atlanta, LLC, Decatur

32720

DeLand Clinical Research Unit, DeLand

32789

Conquest Research LLC, Winter Park

33009

MD Clinical, Hallandale

33032

Homestead Associates in Research, Miami

33175

Ezy Medical Research Co., Miami

48334

Quest Research Institute, Farmington Hills

78229

University of Texas Health Science Center, San Antonio

84058

Aspen Clinical Research LLC, Orem

96817

Hawaii Pacific Neuroscience, Honolulu

06905

New England Institute for Clinical Research, Stamford

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Parexel

INDUSTRY

lead

Annovis Bio Inc.

INDUSTRY

NCT04524351 - Posiphen® Dose-Finding, Biomarker Study in Early Alzheimer's and Parkinson's Patients | Biotech Hunter | Biotech Hunter